Founder and former CEO of the London-based multinational digital health giant Babylon, Ali Parsa, announced the launch of his new company, Quadrivia AI, which will offer clinicians an AI assistant to help with administrative and clinical tasks. 

Quadrivia's offering, Qu, is an AI-enabled personal clinical assistant available in multiple languages designed to support clinicians with various tasks, including patient interactions, routine clinical and administrative tasks, continuous monitoring and support, decision-making, and chronic and postoperative care. Qu is currently in beta testing.

"We assembled an experienced team of scientists, technologists, and clinical innovators across the globe to address the main challenge in healthcare: the structural imbalance between the elastic demand from our communities and the constrained supply of our clinicians. Recent developments in AI, while still in their infancy, offer hope that we can finally address this imbalance by creating an elastic source of clinical supply support. What matters now is how this is done to benefit all in need," Parsa said in a LinkedIn post. 

"Qu has only just begun its journey and still has much to learn. We invite clinicians and carers everywhere to join us to test Qu, share feedback on what needs fixing, and help shape it. Once the foundation is right, we will open Qu for every clinician everywhere, enabling each to make it their own personal AI assistant and customize it according to their needs and way of working. This is just the beginning."

THE LARGER TREND

Babylon, which also offered a digital health chatbot, went public through a $4.2 billion special purpose acquisition company (SPAC) merger with Alkuri Global Acquisition in 2021. 

In May 2023, Babylon announced its plans to go private after it accepted a take-private proposal from AlbaCore Capital on behalf of its affiliate MindMaze. The deal included a secured term loan facility for up to $34.5 million and Babylon's transition from a publicly traded company to a private entity. Babylon also planned to merge with MindMaze. 

Three months later, Babylon reported the deal with MindMaze was not moving forward, and the company would pursue the sale of its U.K. business to third parties and exit its U.S. business.

Babylon subsequently filed for bankruptcy protection in Delaware for two U.S. subsidiaries – Babylon Inc. and Babylon Healthcare Inc. – as the company sought to liquidate its assets. 

In Sept. 2023, the London-based company sold almost all of its U.K. assets to digital-health company eMed Healthcare U.K., a subsidiary of U.S. company eMed. Financial terms of the sale were not disclosed.